Enveric Biosciences, Inc. ENVB
Enveric Biosciences, Inc. (Nasdaq: ENVB) is a CNS/neurology/psychiatry drug developer. Its lead program, EB-003, is in Pre-clinical for depression or other neuropsychiatric disorders. Its next catalyst on record is EB-003: IND filing (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: EB-003 — IND filing (date not stated). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EB-003 (EVM301 Series) | depression or other neuropsychiatric disorders | small molecule | Pre-clinical |
| EVM401 Series | addiction and neuropsychiatric disorders | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.